Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Previously as Chief Medical Officer at Vifor Pharma, Frits successfully led several assets through clinical development to ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

Nigerian highlife musician, Chinedu Okoli, popularly known as Flavour, has seemingly accused his colleague, Kcee of copying ...